We analyzed the TCGA dataset and did overall survival analysis for HOXA9 in AML patients (n = 74) and found that HOXA9 high expressers had a 20% survival rate compared to HOXA9 low expressers which had a 50% survival rate (Figure 9). Here, HOXA9 is linked to acute myeloid leukemia.